News & Analysis on Biopharmaceutical Manufacturing & Bioprocessing Tech
Gilead: Johanna Mercier
By Ben Hargreaves & Maggie Lynch
- Last updated on
The biopharmaceutical company headquartered in California appointed Johanna Mercier as its newest CCO. Mercier will take over the company’s commercial operations at the start of July, filling a new position as the current EVP of Worldwide Commercial Operations, Laura Hamill, leaves the company.
Mercier previously worked in leadership positions across areas such as oncology, inflammation, and neuroscience. Mercier will join Gilead from Bristol-Myers Squibb, where she held the position of president and head of the company’s large markets division.
Mercier said in a statement, “Throughout my career, I have worked to improve care for people with unmet medical needs and I am excited to join a company that shares my commitment to doing what is right for patients – and to advance and commercialise important new medicines.”
Currently, Mercier is a director on the Robert Wood Johnson University hospital board, in addition to her work in the biopharmaceutical research industry.